Transaction Overview

Aetherium is providing comprehensive listing advisory services to MediLink Health Systems, a Malaysian healthtech company that operates a digital health platform connecting patients, providers, and pharmaceutical companies across Malaysia, Singapore, and Indonesia. MediLink is evaluating both SPAC and traditional IPO pathways for a NASDAQ listing, with Aetherium advising on the optimal transaction structure.

Deal Structure

The preliminary enterprise valuation range of two hundred and twenty to two hundred and sixty million dollars is supported by comparable public company analysis and discounted cash flow modeling prepared by an independent valuation firm. Aetherium is evaluating multiple transaction alternatives, including a de-SPAC merger with concurrent PIPE, a traditional IPO with a leading underwriting syndicate, and a direct listing approach. The final recommendation will reflect market conditions, investor appetite, and MediLink’s specific capital requirements.

Strategic Rationale

Southeast Asia’s digital health market is projected to reach thirty billion dollars by 2030, driven by aging populations, rising healthcare costs, and accelerating telemedicine adoption. MediLink’s platform processes over two million patient interactions monthly and has established data-sharing partnerships with major hospital networks in Malaysia and Singapore. A NASDAQ listing would enhance MediLink’s ability to recruit world-class technology talent, fund clinical validation studies, and expand into new therapeutic verticals.

Current Status

Aetherium is conducting preliminary due diligence, preparing financial models, and engaging potential PIPE investors and underwriting banks. The target timeline anticipates a transaction announcement within the next two quarters, subject to market conditions and regulatory considerations.